Tafluposide

Drug Profile

Tafluposide

Alternative Names: F 11782

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Class Antineoplastics
  • Mechanism of Action DNA topoisomerase I inhibitors; DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in France (IV)
  • 09 Nov 2007 Data presented at the 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2007) added to the adverse events and Cancer therapeutic trials sections
  • 06 Aug 2007 This compound is still undergoing active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top